Oncology

Back to articles

Venetoclax shows promise for high-risk CLL

KEY POINT

Venetoclax (Venclexta—AbbVie, Genentech), a new oral selective blood cell lymphoma-2 (BCL-2) protein inhibitor, induced a high rate of response in patients with high-risk chronic lymphocytic leukemia (CLL).